狼疮疾病生物标志物研究:大胆撤药策略或可减少背景免疫抑制剂对临床试验的干扰
该研究纳入41例活动性非器官威胁性SLE flare患者,暂时给予激素并撤除背景免疫抑制剂,评估至疾病复发时间与安全性;低/高基线活动度患者中位至复发时间分别为71/45天,98%在6个月内复发,所有复发均治疗并在6周内缓解,无严重不良事件。基线免疫抑制剂对Th17和B淋巴细胞刺激物的影响因IFN特征而异。
要点
- 活动性非器官威胁性SLE试验中可安全撤除背景治疗,复发者视为无应答并恢复标准治疗。
- 低或高基线活动度患者中位至复发时间分别为71或45天,98%在6个月内复发。
- 所有复发均治疗并在6周内缓解,无因复发或感染导致的严重不良事件。
核心结论
- 活动性非器官威胁性SLE试验可安全撤除背景治疗,若患者复发则判定为无应答并恢复标准治疗。
- 标准治疗的免疫学效应在IFN定义的不同亚组间存在差异。
研究设计与样本
- 研究纳入41例活动性非器官威胁性SLE flare患者(A组),暂时给予激素并撤除背景免疫抑制剂,评估至疾病复发时间与安全性。
- 另纳入62例单次采样患者(B组),与A组一起通过多重组装分析、酶联免疫吸附试验和mRNA阵列研究标准治疗的免疫学影响。
主要发现
- 低或高基线疾病活动度患者的中位至复发时间分别为71或45天。
- 41例患者中40例(98%)在6个月内出现疾病复发。
- 所有复发均得到治疗并在6周内缓解,无因复发或感染导致的严重不良事件。
- I型干扰素(IFN)、Th17和B淋巴细胞刺激物通路同步变化。
- 基线免疫抑制剂对Th17和B淋巴细胞刺激物的影响因IFN特征而异。
临床怎么用
- 在活动性非器官威胁性SLE临床试验中,可考虑撤除背景免疫抑制剂,将复发者判定为无应答并恢复标准治疗。
- 根据IFN特征区分SLE亚组,可能有助于优化治疗组合。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Molecular medicine raised expectations for strategically targeted biologic agents in systemic lupus erythematosus (SLE), but clinical trial results have been disappointing and difficult to interpret. Most studies add investigational agents to various, often effective, standard therapy immunosuppressants used at baseline, with unknown treatment interactions. Eliminating polypharmacy in trials of active lupus remains controversial. We undertook the Biomarkers of Lupus Disease study to test withdrawal of immunosuppressants as a novel approach to rendering SLE trials interpretable. METHODS: In 41 patients with active, non-organ-threatening SLE flare (group A), temporary steroids were given while background immunosuppressants were withdrawn. Time to loss of disease suppression (time to disease flare) and safety were evaluated; standard therapy was immediately resumed when symptoms recurred. Immunologic impacts of standard therapy were studied at baseline by multiplex assay, enzyme-linked immunosorbent assay, and messenger RNA array in group A patients plus 62 additional patients donating a single sample (group B). RESULTS: Patients with lower or higher baseline disease activity had median times to flare of 71 or 45 days, respectively; 40 of 41 patients (98%) had disease flares by 6 months. All flares were treated and resolved within 6 weeks. No serious adverse events occurred from flare or infection. Type I interferon (IFN), Th17, and B lymphocyte stimulator pathways tracked together. Baseline immunosuppressants had distinct impacts on Th17 and B lymphocyte stimulator, depending on IFN signature. CONCLUSION: Trials in active, non-organ-threatening SLE can safely withdraw background treatments if patients who have disease flares are designated nonresponders and returned to standard therapy. Immunologic effects of standard therapy vary between IFN-defined subsets. These findings provide a strategy for minimizing or optimizing treatment combinations in lupus trials and clinical care.
引用
- Merrill JT, Immermann F, Whitley M, et al. The Biomarkers of Lupus Disease Study: A Bold Approach May Mitigate Interference of Background Immunosuppressants in Clinical Trials. Arthritis Rheumatol. 2017. PMID: 28257602. doi:10.1002/art.40086
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。